Overview

A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)

Status:
Completed

Trial end date:
2009-12-01

Target enrollment:

Participant gender:

Summary

This study will evaluate four different modified release formulation to estimate the amount of dimebon available to the body relative to the current dimebon formulation that is given three times a day. The results of this study will help inform and guide further formulation development efforts with the ultimate goal of reducing dose frequency to once-a-day or twice-a-day.

Phase:

Phase 1

Details

Lead Sponsor:

Pfizer

Collaborator:

Medivation, Inc.